Injectability analysis of high concentration protein formulations by extending shear-rate range in microfluidic quartz viscometers

通过扩展微流控石英粘度计的剪切速率范围来分析高浓度蛋白质制剂的可注射性

• 批准号: 10080997
• 负责人: Zehra Parlak
• 金额: $ 25万
• 依托单位: QATCH TECHNOLOGIES, LLC
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10080997
• 关键词: Abate; Acoustics; Address; Algorithms; Antibody Therapy; Behavior; Biological Products; Blood capillaries; Data; Development; Devices; Dimensions; Dose; Ensure; FDA approved; Failure; Formulation; Frequencies; Health Care Costs; Height; Home environment; Industry; Injectable; Injections; Intravenous infusion procedures; Investments; Laws; Lead; Length; Liquid substance; Measurement; Measures; Microfluidics; Modulus; Monoclonal Antibodies; Motion; Patient Preferences; Patients; Phase; Positioning Attribute; Problem Solving; Proteins; Quartz; Research; Resolution; Rheology; Risk; Sampling; Side; Small Business Innovation Research Grant; Subcutaneous Injections; Surface; System; Techniques; Technology; Testing; Therapeutic; Thick; Thinness; Time; Viscosity; base; candidate selection; cost; drug development; early screening; improved; innovation; manufacturability; milliliter; preclinical development; protein protein interaction; research and development; scale up; screening; sensor

The objective of this SBIR Phase I proposal is to expand the viscosity measurement range of QATCH’s innovative nanovisQTM technology for accurate injectability and manufacturability screening of protein-based therapeutics. This objective is motivated by the needs of the growing protein-based biopharmaceutical therapeutics industry (with global market size over $80 billion). Protein-based therapeutics are administered as high concentration formulations due to the volume constraints of subcutaneous injections. However, increased protein-protein interactions at these high concentrations can cause injectability and manufacturability issues, which cannot be determined at early stages of drug development due to the high sample volume requirements of conventional rheology techniques. By developing a wide shear rate range, low volume viscometer, protein molecules can be optimized for injectability/manufacturability and candidates with better developability can be selected for scaling-up. This proposal is significant because the proposed device can assess injectability of protein formulations earlier in drug development than existing technology and consequently reduce the time and cost of R&D spent in developing new, injectable protein-based therapeutics considerably. In preliminary studies, nanovisQTM, which is a microfluidic capillary viscometer with acoustic sensing, has been shown successful in measuring viscosity at low and very high shear-rates simultaneously using less than 10 microliters in 2 minutes. QATCH is proposing to 1) expand the low shear-rate range of nanovisQTM by improving the time-resolution and the minimum detectable flow length, 2) increase the detectable viscosity range of high shear-rates by developing a post-processing algorithm, and 3) compare injection forces calculated by nanovisQTM results and injection force measurements. With the expanded shear-rate and viscosity range, nanovisQTM should be able to identify critical shear-rates, power-law coefficients, and high and low plateau viscosities of protein-based therapeutics.

SBIR第一期提案的目的是扩大QATCH的粘度测量范围